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C O R O N A V I R U S
Immunization with RBD-P2 and N protects against 
SARS-CoV-2 in nonhuman primates
So-Hee Hong1†, Hanseul Oh2†, Yong Wook Park3†, Hye Won Kwak1†, Eun Young Oh4†‡,  
Hyo-Jung Park1†, Kyung Won Kang4, Green Kim2, Bon-Sang Koo2, Eun-Ha Hwang2,  
Seung Ho Baek2, Hyeong-Jun Park1, Yu-Sun Lee1, Yoo-Jin Bang1, Jae-Yong Kim1, Seo-Hyeon Bae1,  
Su Jeen Lee3, Ki-Weon Seo3, Hak Kim3, Taewoo Kwon3, Ji-Hwan Kim3, Seonghwan Lee3, 
Eunsom Kim3, Yeonhwa Kim4‡, Jae-Hak Park5, Sang-In Park6, Marta Gonçalves7,  
Byung Mook Weon7, Haengdueng Jeong8, Ki Taek Nam8, Kyung-Ah Hwang9, Jihye Kim10, 
Hun Kim3, Sang-Myeong Lee*‡, Jung Joo Hong2*, Jae-Hwan Nam1*
Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), various vaccines are being 
developed, with most vaccine candidates focusing on the viral spike protein. Here, we developed a previously 
unknown subunit vaccine comprising the receptor binding domain (RBD) of the spike protein fused with the 
tetanus toxoid epitope P2 (RBD-P2) and tested its efficacy in rodents and nonhuman primates (NHPs). We also 
investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy. Immunization 
with N and RBD-P2 (RBDP2/N) + alum increased T cell responses in mice and neutralizing antibody levels in rats 
compared with those obtained using RBD-P2 + alum. Furthermore, in NHPs, RBD-P2/N + alum induced slightly 
faster SARS-CoV-2 clearance than that induced by RBD-P2 + alum, albeit without statistical significance. Our study 
supports further development of RBD-P2 as a vaccine candidate against SARS-CoV-2. Also, it provides insights re-
garding the use of N in protein-based vaccines against SARS-CoV-2.
INTRODUCTION
Coronavirus disease 2019 (COVID-19), a disease caused by severe 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is con-
tinuously spreading worldwide and has become a serious threat to 
global health. Therefore, an effective vaccine against SARS-CoV-2 
is urgently needed, while only a handful have already been approved. 
The SARS-CoV-2 genome encodes four structural proteins—spike 
(S), membrane (M), envelope (E), and nucleocapsid (N) (1). Similar 
to the S protein of SARS-CoV, the S protein of SARS-CoV-2 mediates 
the entry of the virus into the host cell. The S protein binds to the 
angiotensin-converting enzyme (ACE) receptor on the host cell 
through its receptor binding domain (RBD) (1, 2). As neutralizing 
antibodies against the RBD can block the binding of the virus to 
host cells, the RBD is considered the main target antigen for vaccines 
against SARS-CoV-2 (3, 4). Furthermore, RBD-based vaccines are 
expected to be safer than S protein–based vaccines, as they are not 
likely to induce T helper 2 (TH2)–type immunopathology through 
antibody-dependent enhancement (5–7).
The N proteins of coronaviruses are highly immunogenic and 
are abundantly expressed throughout the course of the infection 
(8). According to a recent study, antibodies against the N protein 
are more sensitive indicators than anti–S protein antibodies for the 
detection of early SARS-CoV-2 infection (9). Moreover, the N protein 
of SARS-CoV-2 is believed to induce T cell responses. An adenovi-
ral vector encoding the N protein induced T cell responses in rhesus 
monkeys, and mice vaccinated with the N protein exhibited T cell 
proliferation and cytotoxic T cell responses (10, 11). However, in vivo 
protection conferred by vaccines containing the N protein has not 
yet been experimentally validated. Thus, it is still ambiguous whether 
immunization with the N protein combined with RBD would manifest 
better or worse protective effects.
Currently, numerous SARS-CoV-2 vaccines based on different 
platforms are being developed owing to urgent demand and import-
ance (12). Subunit vaccines are the most commonly used vaccines 
owing to their safety parameters. Many commercially approved 
vaccines against diseases caused by viruses such as human papilloma-
virus, hepatitis B, influenza, and varicella zoster are being manufactured 
using this platform (13). However, because of their lower immuno-
genicity compared with that of live attenuated vaccines, subunit 
vaccines need adjuvants, carriers, or engineering of the proteins to 
boost their immunogenicity (14).
Here, we developed a previously unidentified SARS-CoV-2 sub-
unit vaccine (RBD-P2) by fusing the P2 epitope of tetanus toxoid 
with the RBD of the spike protein to increase its immunogenicity. A 
previous study shows that the inclusion of the universal toxoid 
CD4+ T cell epitope P2 substantially increases the immunogenicity 
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of a recombinant rotavirus subunit vaccine (15). Furthermore, we 
tested the efficacy of RBD-P2 with or without the N protein in mice, 
rats, and nonhuman primates (NHPs).
RESULTS
Characterization of recombinant RBD-P2 and N
We designed and synthesized RBD fused with the P2 epitope of tetanus 
toxoid (RBD-P2) as a vaccine candidate against SARS-CoV-2. The 
RBD-P2 and N proteins of SARS-CoV-2 were expressed and puri-
fied using High Five insect cells and the baculovirus-mediated Bac-to-
Bac expression system. A human albumin signal peptide sequence 
was fused with the RBD-P2 and N protein sequences to enable the 
secretion of the proteins (Fig. 1A and fig. S1). Recombinant RBD-P2 
and N proteins were successfully purified from the culture super-
natant (Fig. 1B). The purity of the final protein preparation was 
approximately 90%, and the molecular weights of the purified RBD-P2 
and N proteins were approximately 32  and 53 kDa, respectively 
(Fig. 1B). Both proteins were presumably glycosylated as their esti-
mated molecular weights were higher than the theoretical molecu-
lar weights calculated on the basis of the amino acid sequences. The 
binding ability of RBD-P2 was measured using a functional enzyme- 
linked immunosorbent assay (ELISA). Immobilized RBD-P2 (2 g/ml) 
bound to human anti–SARS-CoV-2 RBD-neutralizing antibody 
(ACROBiosystems, catalog no. SAD-S35) and mouse anti–SARS-
CoV-2 spike-neutralizing antibody (Sino Biological, catalog no. MM57) 
(Fig. 1C). The median effective concentration (EC50) of RBD-P2 for 
the human antibody was 56.5 g/ml, and that for the murine anti-
body was 20 g/ml. These values were similar to those of RBD-positive 
protein (Sino Biological, catalog no. 40592-V08B; EC50: 49.4 g/ml 
for human antibody and EC50: 22.3 g/ml for murine antibody). 
The binding affinity of RBD-P2 for human ACE2 (hACE2) was cal-
culated as follows: KD (equilibrium constant) = 4.1 nM with Kon = 
1.1 × 105 M−1 S−1 and Koff = 4.5 × 10−4 s−1 (Fig. 1D). The binding 
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Fig. 1. Characterization of RBD-P2 and N. (A) Schematic view of RBD-P2 and N. Different domains and elements are marked, including the signal peptide (SP), RBD, 
linker, and P2, and the relevant GenBank accession numbers are indicated. (B) Representative elution chromatograph of the recombinant RBD-P2 and N proteins using 
three columns (anion exchange, hydrophobic interaction, and multifunctional resin). Inset figures show the SDS–polyacrylamide gel electrophoresis (blue) and Western 
blot (gray) analyses of the eluted proteins. (C) ELISA binding curves of human SARS-CoV-2–neutralizing antibodies (Ab) to RBD and anti-spike mouse monoclonal anti-
bodies (mAb) to RBD-P2. RBD-positive is a commercially procured RBD protein (Sino Biological, catalog no. 40592-V08B). OD, optical density. (D) Real-time binding profile 
of purified RBD-P2 protein to hACE2 and anti-RBD monoclonal antibodies obtained using an Octet system.
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affinity of RBD-P2 for anti-RBD monoclonal antibody was calcu-
lated as follows: KD = 22.3 nM with Kon = 7.5 × 104 M−1 S−1 and 
Koff = 1.7 × 10−3 s−1 (Fig. 1E).
Analysis of humoral and cellular immune responses in mice 
immunized with RBD-P2 or RBD-P2/N
In this study, we chose alum as an adjuvant because of its strong 
safety record (16). First, we compared the immune responses 
of RBD-P2 and RBD. RBD was expressed and purified from insect 
cells using the Bac-to-Bac expression system as described for RBD-P2 
(details are in Materials and Methods). After immunization in rats, 
RBD-P2 + alum induced a significantly higher neutralizing antibody 
titer than RBD + alum (fig. S2B). Therefore, all vaccine tests were 
conducted using RBD-P2. We confirmed the complex formation of 
RBD-P2 and RBD-P2/N with alum by using holotomography and 
dynamic light scattering (fig. S3A). As shown in fig. S3A, unlike 
alum alone, which had more scattered clusters, both RBD-P2 and 
RBD-P2/N with alum clustered in long rod-like shapes. We also 
used dynamic light scattering analysis to confirm the successful for-
mulation of RBD-P2 and RBD-P2/N with alum. We could detect 
one main peak in both RBD-P2 + alum and RBD-P2/N + alum. This 
result indicates that most of the proteins formed a complex with 
alum (fig. S3B).
To evaluate the stability of alum/protein (RBD-P2 or RBD-P2/N) 
complexes, we stored alum-adjuvanted RBD-P2 or RBD-P2/N at 4° 
to 8° or 37°C for 3 months. Alum-formulated samples were centri-
fuged at different time points, and the supernatants were discarded. 
Concentrations of remaining protein were measured using the Bi-
cinchoninic acid (BCA) assay. On the basis of the results, both RBD-P2 
and RBD-P2/N formulated with alum maintained about 95% sta-
bility at least until 3 months at 4° to 8°C, and about 63% stability 
at 37°C for at least 7 days. This means that formulation of RBD-P2 
or RBD-P2/N with alum is very stable at the proper temperature.
To test the potential of RBD-P2 as a SARS-CoV-2 vaccine candi-
date, mice were intramuscularly immunized twice with 30 g of 
RBD-P2 + alum (mG2) 3 weeks apart. To confirm the effectiveness 
of the N protein, mice were immunized with 30 g of RBD-P2 and 
3 g of N + alum (mG3), designated as RBD-P2/N. Mice immu-
nized twice with alum without antigen were designated as mG1. All 
mice were euthanized 3 weeks after the booster dose (Fig. 2A).
To assess humoral responses, serum samples were collected at 
the time of euthanization, and RBD-P2– and N-specific immuno-
globulin G1 (IgG1) and IgG2c antibody levels were analyzed using 
ELISA. As shown in Fig. 2  (B  to E), RBD-P2 + alum–immunized 
mice exhibited induction of IgG1 and IgG2c against RBD-P2. The 
fusion of N with RBD-P2 (RBD-P2/N) slightly reduced the levels of 
RBD-specific IgG1 but not IgG2c (Fig. 2, B to E). Understandably, 
N-specific antibodies were detected only in mG3.
Next, to determine cell-mediated immune responses, splenocytes 
from immunized mice were stimulated with a mix of SARS-CoV-2 
RBD-P2 and N peptide mix (table S1) for 2 days to detect antigen- 
specific T cell responses. As shown in Fig. 2 (F to H), the percentag-
es of both CD4+ and CD8+ CD44hiCD62Lhi central memory type T 
cells (TCM) were increased in mG2 and mG3 compared with those 
in mG1. The expression of CD103, a marker of tissue-residential 
memory T cells, was increased in the CD4+ TCM of mG2 and mG3 
(Fig. 2F). The expression of CD69, a T cell activation marker, was 
increased only in CD4+ T cells of mG3 and not in mG1and mG2 
(Fig. 2G). To further evaluate the TH1/2 balance, interferon- 
(IFN-)– and interleukin-4 (IL-4)–producing cells were measured 
by enzyme-linked immunosorbent spot (ELISpot) assays. Notably, 
IFN-– and IL-4–producing cells were increased in mG3 compared 
with their numbers in mG2, even when splenocytes were stimulated 
with RBD alone (Fig. 2H). To test whether immunization with the 
N protein could induce protective immunity, hACE2 mice were 
intramuscularly immunized twice with 30 g of the N protein with 
alum at 2-week intervals and challenged with SARS-CoV-2 1 week 
after the second immunization (fig. S4A). Viral titers in the lungs 
were reduced in N protein–immunized mice, and parenchymal in-
flammation scores of mG2 were slightly reduced compared with those 
of mG1. Thus, immunization with N protein + alum could induce a 
certain degree of protective effect against SARS-CoV-2 (fig. S4, B to E).
Additional immunization with the N protein increased 
the levels of neutralizing antibodies in rats
To further assess the immune responses elicited by RBD-P2 or 
RBD-P2/N, rats were injected with 30 or 50 g of RBD-P2 (rG2 and 
rG3) or in combination with N at a ratio of 10:1 (rG4 and rG5) to-
gether with alum. The immunization was performed twice (with a 
3-week interval in between), and the rats were euthanized 6 weeks 
after the first injection (Fig. 3A). Both anti–RBD-P2 IgG and anti-N 
IgG were detected 6 weeks after the first immunization. Immuniza-
tion with 50 g of RBD-P2 + alum induced slightly higher levels of 
RBD-P2–specific antibodies than that induced by 30 g RBD-P2 + 
alum, although the difference was not statistically significant (Fig. 3B). 
RBD-P2/N (rG4 and rG5) + alum immunization yielded an approx-
imately 20 to 50% increase in reduction rates compared with those 
achieved using each of its RBD-P2 counterparts (rG2 and rG3, re-
spectively) (Fig. 3C). The number of IFN-–producing cells in the 
splenocytes of immunized rats increased in all immunized groups 
(rG2 to rG5) compared with that observed in rG1 after stimulation 
with RBD-P2, the peptide mix, or the P2 peptide (table S1). However, 
no significant differences were observed between RBD-P2/N and 
RBD-P2 groups (Fig. 3D).
To assess the immunogenicity and toxicity of RBD-P2 or RBD-
P2/N in rats, the animals were immunized three times at 2-week 
intervals with RBD-P2 + alum (rG2) or RBD-P2/N + alum (rG3) 
according to the guidelines for SARS-CoV-2 vaccine development 
established by the Korean Food and Drug Administration (fig. S5A). 
In this experiment, rG3 produced higher levels of anti–RBD-P2 IgG 
than rG2 at 2 and 4 weeks after the first immunization in females 
(fig. S5B). However, 6 and 8 weeks after immunization, the levels of 
anti–RBD-P2 IgG produced in response to immunization with rG2 
were markedly increased and reached levels similar to those of rG3. 
In addition, biochemical analysis revealed that neither RBD-P2 + 
alum nor RBD-P2/N + alum induced significant toxicity (fig. S5C).
NHPs immunized with RBD-P2 or RBD-P2/N were protected 
from SARS-CoV-2 challenge
Last, we tested the efficacy of our vaccine candidates in NHPs. Three 
NHPs per group were intramuscularly administered with either 
RBD-P2 + alum (nG2) or RBD-P2/N + alum (nG3) at 0 and 3 weeks. 
Control NHPs (nG1) were administered only with alum adjuvant 
(Fig. 4A). Three weeks after immunization, the levels of total IgG 
were increased approximately 100-fold in nG2 and nG3, and at 
6 weeks, an approximately 2000- to 3000-fold increase in total IgG 
levels was detected in both nG2 and nG3. At 9 weeks, total IgG levels 
were reduced compared to those at 6 weeks. Total IgG levels of nG3 
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were slightly higher than those of nG2 (Fig. 4B). Neutralizing anti-
body responses against SARS-CoV-2 were markedly increased in 
nG2 and nG3 at 6 weeks; however, they were reduced at 9 weeks in 
both nG2 and nG3. Although additional immunization with N in-
creased the neutralizing antibody titers in NHPs, the increase was 
not statistically significant (Fig. 4C). Notably, the neutralizing anti-
body titers induced by RBD-P2 or RBD-P2/N were significantly 
higher than those of a panel of serum samples from conva-
lescent patients [at 6 weeks, the geometric mean titer (GMT) of 
nG2 = 507.96 and the GMT of nG3 = 1015.93; at 9 weeks, the GMT 
of nG2  =  163, the GMT of nG3  =  320, and the overall convalescent 
serum of GMT = 109.4; all GMT values were calculated on the basis 
of plaque reduction neutralization test (PRNT50) values] (Fig. 4C).
To assess T cell responses, the number of IFN-–producing cells 
in peripheral blood mononuclear cells (PBMCs) were evaluated at 3 
and 6 weeks after immunization. The average number of RBD-P2–
specific IFN-–producing cells was slightly higher in nG3 than in 
nG2 at 3 and 6 weeks. As expected, IFN-–producing cells in re-
sponse to the N protein were detected only in nG3, as the animals in 
this group were immunized with N (Fig. 4D). We also measured the 
levels of various cytokines in the supernatants of PBMCs from 




















































































Alum + + +
Non RBD-P2 N peptide


































































































































































































































































































Fig. 2. Humoral and cellular immune responses induced by RBD-P2 or RBD-P2/N in mice. (A) Overall study design. Mice were intramuscularly immunized with 
RBD-P2 (30 g per mouse) + alum or RBD-P2 (30 g per mouse)/N (3 g per mouse) + alum at 0 and 3 weeks and euthanized at 6 weeks. (B and D) RBD-P2– and N-specific 
IgG1 and IgG2c levels were measured by ELISA at the time of sacrifice (n = 5). The fold change represents an increase in the test group (mG2 and mG3) proportional to the 
average OD450 value of the control group (mG1). (C and E) Sera were tested at different dilutions to detect IgG1 and IgG2c against RBD-P2 and N (n = 5). (F to H) Spleno-
cytes (5 × 105) from each mouse were cultured in the presence of RBD-P2 and peptide mix (table S1) together or separately for 2 days (n = 5). (F and G) Frequency of TCM 
and expression of CD103 and CD69 in T cells analyzed using flow cytometry (n = 5). (H) Number of IFN-– and IL-4–producing cells and the activities of stained cells esti-
mated using the AID EliSpot Reader (n = 5 mice). *P < 0.05, **P < 0.01, and ***P < 0.001.
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factor– production in PBMCs from nG2 and nG3 was increased 
compared to those of nG1 (Fig. 4E).
To confirm the protective effect of RBD-P2 + alum (nG2) and 
RBD-P2/N + alum (nG3), NHPs were challenged with a total of 
10 ml of virus [2.6 × 106, 50% tissue culture infectious dose 
(TCID50)/ml] via intratracheal (4 ml), oral (5 ml), conjunctival 
(0.5 ml), and intranasal (0.5 ml) routes at 9 weeks after the first 
immunization. Of note, RBD-P2/N + alum–immunized NHPs 
showed slightly faster SARS-CoV-2 clearance in throat and lung sam-
ples than that induced by RBD-P2 + alum, although it was not sta-
tistically significant (Fig. 4, F and G). Also, live SARS-CoV-2 particles 
were not detected in the lungs of either nG2 or nG3 and were barely 
detectable in the nose and throat in postchallenges (Fig. 4, F and G).
Moreover, the body temperature of immunized NHPs (nG2 and 
nG3) was not increased compared with that of nG1 after the virus 
challenge (Fig. 4H). In addition, SARS-CoV-2 genomic RNA (gRNA) 
was reduced in total lung analyses of nG2 and nG3 compared with 
that in the lungs of nG1 (fig. S6A). Further, nG3 showed lower 
gRNA levels than nG2 in throat swabs and some parts of lung tissue 
(fig. S6B). NHPs did not show any significant weight loss after chal-
lenge (fig. S7A). Hematological and biochemical analyses, including 
absolute lymphocyte counts, revealed no notable changes in the 
vaccinated groups (nG2 and nG3) compared with those in control 
NHPs (nG1) (fig. S7B).
DISCUSSION
Currently, many types of vaccine candidates against SARS-CoV-2, 
including inactivated, vectored, nucleotide-based, and recombi-
nant, are being tested in preclinical or clinical trials. Most of these 
candidates involve at least a portion of the spike protein, and it is 
still unclear whether immunization in combination with the N 
protein of SARS-CoV-2 would be beneficial for protection against 
SARS-CoV-2 challenges (17–19). In this study, we developed a 
previously unknown subunit vaccine against SARS-CoV-2 that in-
volves the RBD linked to the P2 epitope of tetanus toxoid to en-
hance immunogenicity. Consistent with the previous finding, we noted 
higher neutralizing antibody titers against SARS-CoV-2 in rats 
when immunized with RBD-P2 than that with RBD. In addition, 
RBD-P2 + alum effectively induced a neutralizing antibody re-
sponse in NHPs and provided protection against SARS-CoV-2 
challenge. Thus, it seems that immunization with RBD-P2 + alum 
can induce effective and sufficient virus-neutralizing activity and provide 
protection. However, we could not ascertain whether RBD-P2 + alum 
induces long-term humoral immunity, as NHPs were chal-
lenged with SARS-CoV-2 6 weeks after boosting.
N proteins are considered highly immunogenic, and the gene 
encoding the N protein is more stable than that encoding the spike 
protein (20). A DNA vaccine encoding SARS-CoV N protein was 
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Fig. 3. Humoral and cellular immune responses elicited by RBD-P2 or RBD-P2/N in rats. (A) Overall study design. Rats were intramuscularly immunized with RBD-P2 
(30 or 50 g per rat) + alum or RBD-P2 (30 or 50 g per rat)/N (3 or 5 g per rat) + alum at 0 and 3 weeks and euthanized 6 weeks after immunization (n = 10). (B) RBD-P2– or 
N-specific total IgG levels were measured using ELISA at the time of euthanization. (C) SARS-CoV-2–neutralizing activity (reduction rate) of serum from immunized rats 
was determined using the standard plaque reduction neutralization test (PRNT50) 6 weeks after the first immunization. (D) Splenocytes (5 × 105) from each rat were seeded 
and stimulated with RBD-P2 or P2 peptides (table S1) for 60 hours before measuring the number of IFN-–producing cells. *P < 0.05, **P < 0.01, and ***P < 0.001.







Hong et al., Sci. Adv. 2021; 7 : eabg7156     28 May 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 10
responses in C57BL/6 mice and achieved a significant reduction in 
viral titers following challenge (10). On the contrary, Buchholz et al. 
reported that immunization with the N protein did not induce a 
neutralizing antibody response and failed to protect against infec-
tion in a SARS-CoV hamster model (21). To test whether the inclu-
sion of the N protein as a vaccine antigen could generate more 
balanced immune responses, we compared the immune responses 
elicited by RBD-P2 and RBD-P2/N immunization in three different 
animals—mice, rats, and NHPs. Of note, RBD-P2/N + alum–
immunized mice exhibited enhanced T cell–mediated immune re-
sponses. Immunization with the N protein and RBD-P2 increased 
CD69 expression in CD4+ T cells as well as IFN- and IL-4 produc-
tion in mice. In NHPs, PBMCs in RBD-P2/N + alum–immunized 
animals produced IFN- when they were stimulated with the N 
protein; however, production of TH2-type cytokines (IL-4, IL-5, and 
IL-13) was very low. Consistent with these findings, the numbers of 
IFN-–producing cells were increased in the RBD-P2/N  +  alum 
group. Furthermore, RBD-P2/N + alum–immunized NHPs showed 
faster SARS-CoV-2 clearance than that of RBD-P2 + alum immu-
nized NHPs in throat swab samples. Thus, increased T cell activa-
tion and TH1-prone responses may result in faster viral clearance 
and constrain viral spread.
In addition to inducing T cell responses, we expect that vaccines 
based on the N protein may provide effective protection against 
SARS-CoV-2 variants since the N protein is more conserved than 
the spike protein. Currently, SARS-CoV-2 spike protein variants 
have emerged, and it was reported that these variants are resistant 
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Fig. 4. Immunization with RBD-P2 or RBD-P2/N protected NHPs from SARS-CoV-2 challenge. (A) Overall study design. NHPs were intramuscularly immunized with 
alum-adjuvanted RBD-P2 (50 g) or RBD-P2 (50 g)/N (5 g) at 0 and 3 weeks and challenged with SARS-CoV-2 at 9 weeks after the first immunization. All NHPs were eu-
thanized 3 days after the challenge (n = 3). (B) Fold change in IgG levels of NHPs measured by ELISA at 3, 6, and 9 weeks. (C) SARS-CoV-2–neutralizing activity of plasma 
from immunized NHPs at 3, 6, and 9 weeks after the first immunization, and convalescent patients were analyzed using the standard PRNT50. NHPs: n = 3; patients: n = 31. 
(D) 3 and 6 weeks after immunization, PBMCs were isolated from immunized NHPs and stimulated with RBD-P2, N, or P2 peptides (table S1) for 60 hours before measuring 
the number of IFN-–producing cells. (E) PBMCs were isolated from immunized NHPs 6 weeks after immunization and stimulated with RBD-P2 or N for 3 days. Cytokine 
concentrations were measured in cell culture supernatants using multiplex analysis. (F and G) Nonvaccinated (nG1), RBD-P2 + alum–vaccinated (nG2), and RBD-P2/N + alum–
vaccinated (nG3) NHPs were challenged with SARS-CoV-2 at the TCID50 of 2.6 × 106. The challenge was provided through intratracheal, oral, conjunctival, and intranasal 
routes at 9 weeks after the first immunization. Samples were collected from nasal swabs, throat swabs, and lung tissue at multiple time points after the challenge, and live 
virus titers were determined by calculating TCID50 values. (H) Body temperature of NHPs after the challenge. *P < 0.05, **P < 0.01, and ***P < 0.001.
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an RBD-P2/N immunization may be advantageous in overcoming 
escape mechanisms of SARS-CoV-2 because of gene mutations en-
coding the spike protein.
There were limitations to this study. We immunized NHPs with 
a relatively high dose of RBD-P2 (50 g) and tested the efficacy of 
the RBD-P2 and N combination only at a 10:1 ratio. Thus, the effec-
tiveness of the N protein could vary depending on the dose of 
RBD-P2. Further studies are needed to determine the optimal dose 
or ratio involving the N protein. Currently, we are evaluating the 
RBD-P2–based subunit vaccine in clinical trials (phase 1, no. 
NBP2001) because RBD-P2 and RBP-P2/N showed similar protec-
tive efficacy in NHPs.
In summary, our data demonstrated that RBD-P2 + alum 
immunization elicits a robust neutralizing antibody response and 
provides complete or near-complete elimination of live SARS-
CoV-2 virus particles. Moreover, our findings provide insight into 




The Bac-to-Bac expression system (Invitrogen, Waltham, MA, USA; 
catalog no. 10359-016) was used to produce SARS-CoV-2 RBD-P2 
and N proteins. The gene sequences of RBD and N were obtained 
from the genome sequence of the Wuhan seafood market pneumo-
nia virus, Wuhan-Hu-1. The gene fragments were synthesized at 
GenScript (Piscataway, NJ, USA) and cloned into the pFastBac vec-
tor, and the recombinant plasmid was prepared using Escherichia 
coli DH5 cells. The recombinant pFastBac plasmid, which served 
as a donor plasmid, was transformed into E. coli DH10Bac compe-
tent cells (Gibco, NY, USA; catalog no. 10361012) harboring a shuttle 
vector (bacmid). The recombinant bacmid was transfected into in-
sect cells to produce recombinant baculoviruses. For virus produc-
tion, Sf9 cells (ATCC CRL-1711TM, lot no. 62058094) derived from 
Spodoptera frugiperda were used. Cell culture supernatant 
was recovered 3 days after transfection to obtain recombinant 
baculoviruses.
Production of RBD-P2 and N protein
Sf9 cells were infected with a baculovirus containing the RBD-P2 
gene and cultured in a flask. After 6 days, the baculovirus was har-
vested by centrifugation and filtration through 0.2-m filters. An 
aliquot of the clarified baculovirus preparation was used for RBD-P2 
antigen production. The titer of the baculovirus was obtained by 
rapid titration assay. High Five cells were cultured in a 10-liter bio-
reactor for RBD-P2 antigen production. The Hi-5 cells were infected 
with baculovirus harboring the RBD-P2 gene at a multiplicity of in-
fection of 1 to 3 and cultured for 3 days. The cells were removed by 
centrifugation and filtration through 0.2-m filters. The RBD-P2 
antigen was purified using three columns—anion exchange, hydro-
phobic interaction, and multifunctional resins—from the separated 
cell culture supernatant. The RBD-P2 antigen was concentrated for 
formulation using the tangential flow filtration (TFF) system. The 
purified RBD-P2 antigen was mixed with alum as an adjuvant at a 
1:10 ratio. The N antigen was produced using the same baculovirus 
and insect system. Its blood vessel invasion and upstream processes 
were the same as those for RBD-P2. The N antigen was purified 
from the separated cell culture supernatant using an anion exchange 
column and concentrated for formulation using the TFF system. 
The formulation for the adjuvant was the same as that for RBD-P2.
Mouse handling and care
Female BALB/c and C57BL/6 mice aged 8  to 10 weeks were pur-
chased from Dae-Han Bio-Link (Eumseong-Gun, Chungchenonbuk-do, 
Republic of Korea) or Samtako (Osan-si, Guenggi-do, Republic of 
Korea). The mice were housed in the animal facility at the Catholic 
University of Korea under specific pathogen–free conditions at 21° 
to 22°C and a 12/12-hour light/dark illumination cycle. The animal 
facility is fully certified by the Korean Association for Laboratory 
Animals, and the mice were handled in accordance with the proto-
cols approved by the Catholic University of Korea. All experimental 
procedures performed on mice in this study followed the guidelines 
of the Institutional Animal Care and Use Committee of the Catholic 
University of Korea (approval nos. CUK-IBC-2020-001, CUK- 
IACUC-2020-014, and CUK-IACUC-2020-015).
Immunization of mice and rats
BALB/C or C57BL/6 mice were intramuscularly injected with 30 g 
of RBD-P2 with or without 3 g of N formulated with 300 g of 
alum (Croda, Yorkshire, UK) twice at 3-week intervals. Sera were 
collected after the mice were euthanized. For the challenge, hACE2 
transgenic mice were intramuscularly injected in the upper thigh 
once with 30 g of N formulated with 300 g of alum two times at 0 
and 2 weeks. The hACE2 transgenic mice were challenged with the 
SARS-CoV-2 virus [5 × 105 plaque-forming units (PFU) per mouse] 
at 3 weeks after the first immunization, and their body weight and sur-
vival rate were determined. All challenged mice were maintained in 
Biosafety Level 3 (BSL-3) facilities at the Korea Zoonosis Research 
Institute of Jeonbuk National University (JBNU). All mouse experi-
mental procedures conducted in this experiment followed the guide-
lines of the Institutional Animal Care and Use Committee of JBNU 
(approval no. JBNU2020-0155).
Rats aged ~8 to 12 weeks were purchased from Orient Bio Inc. 
(Seongnam, Republic of Korea) and were intramuscularly injected 
with 30 or 50 g of RBD-P2 with or without N at a 1:10 ratio. The 
proteins were combined with 300 or 500 g of alum (twice at 3-week 
intervals). Sera were collected from the rats at the indicated time 
points and at the time of sacrifice for the detection of serum anti-
bodies against RBD-P2 and N.
NHP care and study design
Nine Cambodian-origin cynomolgus macaques (Macaca fascicularis; 
three males and six females; aged 6 to 7 years) were used in this 
study. All animals were housed in infrastructure facilities in the 
Korea National Primate Research Centre (KNPRC) at the Korea 
Research Institute of Bioscience and Biotechnology (KRIBB), under 
animal biosecurity level–2 (ABL-2) or ABL-3, as required. Macaques 
were anesthetized with a combination of ketamine sodium (10 mg/kg) 
and tiletamine/zolazepam (5 mg/kg) for immunization, viral chal-
lenges, swabs, and blood collection.
As illustrated in Fig. 4A, the macaques were randomly assigned 
to three sex-balanced groups. The animals were intramuscularly 
immunized in the upper thigh at weeks 0 and 3 with one of the 
following formulations: (i) 500 g of alum (Croda), (ii) 50 g of 
RBD-P2 with 500 g of alum, and (iii) 50 g of RBD-P2 and 5 g of 
N with 500 g of alum. After 6 weeks from the last immunization, 
all animals were challenged with a total of 10 ml of the SARS-CoV-2 
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virus (TCID50 = 2.6 × 106/ml) via intratracheal (4 ml), oral (5 ml), 
conjunctival (0.5 ml), and intranasal (0.5 ml) routes. Clinical exam-
inations, swab sampling, and hematological analysis were conduct-
ed daily until necropsy. Challenged macaques were monitored for 
body weight, rectal temperature, and respiration. Nasopharyngeal 
and oropharyngeal swab samplings were collected in universal viral 
transport medium at 0, 1, 2, and 3 days postinfection (dpi) for virus 
quantification. Hematological data were determined on the basis of 
EDTA-treated whole blood samples using an automatic hematolo-
gy analyzer (Mindray BC-5000, Nanshan, China).
All macaques were euthanized and necropsied at 3 dpi. Lung 
samples were collected at necropsy for viral detection and micro-
scopic examination. All procedures were approved by the KRIBB 
Institutional Animal Care and Use Committee (approval no. KRIBB- 
AEC-20191). All procedures were performed in a biosafety cabinet 
class II in the ABL-3 facility at KNPRC, KRIBB (approval no. 
KRIBB-IBC-20200206).
SARS-CoV-2 culture
The SARS-CoV-2 virus (BetaCoV/Korea/KCDC03/2020, accession 
no. 43326 from the National Culture Collection for Pathogens) was 
propagated in Vero cells in Dulbecco’s modified Eagle’s medium 
(DMEM; Welgene Inc. Gyeongsan-si, Gyeongsangbuk-do, Republic 
of Korea) supplemented with 2% fetal bovine serum (FBS), penicillin 
(10,000 IU/ml), and streptomycin (10,000 IU/ml) in a humidified 
5% CO2 incubator as described in our previous report (23).
Neutralization assay for NHPs
Vero cells were seeded in a six-well plate and incubated at 37°C and 
5% CO2 for 16 to 18 hours. Six weeks after the first immunization, 
plasma samples were inactivated at 56°C for 30 min and 2-fold seri-
ally diluted from 20-fold diluted samples. Diluted plasma samples 
were mixed with SARS-CoV-2 (50 to 100 PFU per well) at 37°C and 
5% CO2 for 1 hour and then inoculated into Vero cells for 1 hour 
under the same incubation conditions. After removing the plasma- 
virus mixture, 1.5% low–melting temperature agarose in DMEM, 
supplemented with 2% FBS, was added, and the cells were incubated 
for 3 days. The cells were fixed with 10% neutral formalin solution 
overnight and stained with 0.1% crystal violet solution. For each 
dilution, the number of plaques was counted, and the percentage of 
neutralization in test samples was compared with that in the control.
Isolation of PBMCs from NHPs
Blood samples were collected in EDTA-containing tubes, 0 and 
2 weeks after immunization. PBMCs were isolated by centrifugation 
at 3500g for 20 min with gentle acceleration using Ficoll-Hypaque 
(Lymphoprep; Axis-Shield, 1114545). Red blood cells in the PBMCs 
were lysed in Ammonium-Chloride-Potassium (ACK) lysis buffer 
(Gibco, Gaithersburg, MD, USA) at 20° to 25°C for 5 min. The PBMCs 
were washed once with flow cytometry staining buffer [1× phosphate- 
buffered saline (PBS) with 2% FBS] and resuspended in RPMI me-
dium supplemented with 10% FBS and penicillin/streptomycin (1×).
Human blood samples
In this study, blood and serum samples were collected from 31 con-
valescent patients with COVID-19 enrolled from Seoul National 
University Hospital, Seoul Metropolitan Government–Seoul 
National University Boramae Medical Center, Kyungpook National 
University Hospital, Chonnam National University Hospital, 
and Chung-Ang University Hospital. The study was approved by 
the Institutional Review Boards of the mentioned hospitals (IRB 
nos. 2042-005-413, CNUH-2020-130, 2020-05-006, and 20–2020-41). 
Serum samples were heat-inactivated (20 min at 60°C) before using 
in binding or neutralizing assays.
Flow cytometry
Mouse splenocytes (1 × 106) were stained in PBS containing 0.5% 
FBS for flow cytometry. In total, 0.5 g of Fc Receptor blocker (anti- 
CD16/CD32 antibody) was added 15 min before fluorochrome- 
conjugated antibody staining. The following antibodies were obtained 
from Invitrogen (Waltham, MA, USA): anti-mouse CD4, CD8, CD44, 
CD62L, and CD103. Anti-mouse CD69 antibodies were purchased 
from BD Bioscience (San Diego, CA, USA). To distinguish live cells 
from dead cells, the cells were stained with Fixable Viability Dye eFluor 
520 (Invitrogen). After washing, the cells were analyzed using a 
Cytek Aurora Flow Cytometer (Cytek, Fremont, CA, USA), and the 
results were interpreted using SpectroFlo software (Cytek).
ELISpot assays
ELISpot assay for mice
Splenocytes of immunized mice were stimulated with 500 ng per well 
of RBD-P2 or 600 ng per well of N peptide mix for 48 hours. IL-4– and 
IFN-–secreting cells were detected using the mouse IL-4 ELISpotBASIC kit 
and the mouse IFN- ELISpotBASIC kit (Mabtech, Nacka Strand, Sweden), 
respectively. The manufacturer’s protocols were followed for these assays.
ELISpot assay for rats
Splenocytes of immunized rats were stimulated with 300 ng per well 
of RBD-P2 or 300 ng per well of P2 peptides for 60 hours. IFN-–
secreting cells were detected using a rat IFN- ELISpot kit (R&D 
Systems, Minneapolis, MN, USA) according to the manufacturer’s 
instructions.
ELISpot assay for NHPs
PBMCs of immunized NHPs were stimulated with 300 ng per well 
of RBD or 300 ng per well of N or 1 g per well of P2 peptides for 
60 hours. IFN-–secreting cells were detected using primate IFN- 
ELISpot kit (R&D Systems) according to the manufacturer’s in-
structions. The resultant spots were counted on a computer-assisted 
AID EliSpot Reader System (AID, Strasburg, Germany).
Mouse ELISA
Antigen-specific IgG1 and IgG2c levels in mouse serum were mea-
sured using ELISA. First, a 96-well plate (Corning, NY, USA) was 
coated with either S, N, or RBD-P2 (100 ng/l) and incubated at 4°C 
overnight. After incubation, the wells were blocked with 100 l of 
blocking buffer (PBS containing 1% bovine serum albumin) at room 
temperature for 1 hour. Diluted serum samples were added to the 
wells, and the plates were incubated at room temperature for 2 hours. 
After incubation, the wells were washed thrice with 200 l of PBS 
containing 0.05% Tween 20 (PBS-T). Horseradish peroxidase–
conjugated anti-mouse IgG1 (Bethyl Laboratories, Montgomery, TX, 
USA) and IgG2c (Novus Biologicals, Centennial, CO, USA) anti-
bodies (diluted 1:1000 to 1:10,000 in PBS) were added to the plates, 
which were then incubated at room temperature for 1 hour. After 
three washes with PBS-T, tetramethylbenzidine substrate was added, 
and the plates were further incubated for 15 min before stopping the 
reaction with 2 N H2SO4. The optical density at 450 nm was mea-
sured using a GloMax Explorer microplate reader (Promega, Seoul, 
Republic of Korea).
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Plaque reduction neutralization test
Sera of immunized mice, NHPs, and convalescent patients were se-
rially diluted from 1:10 to 1:5120 with serum-free medium. Virus- 
serum mixtures were prepared by mixing 100 PFU of SARS-CoV-2 
with the diluted serum samples, and the mixtures were incubated at 
37°C for 1 hour. Vero cells were inoculated with the virus-serum 
mixtures, and the plates were incubated at 37°C in the presence of 
5% CO2 for 1 hour. After virus absorption, the agar overlay medium 
was added, and the plates were incubated at 37°C under 5% CO2 for 
3 days. The cells were stained with 0.1% crystal violet solution 
(Sigma-Aldrich, St. Louis, MO, USA), and the plaques were counted. 
The percentage of neutralization represented the reduction value, 
which was calculated as the number of plaques in 100 PFU of the 
virus-infected well per number of plaques in the virus-serum 
mixture–infected well (×100).
Viral quantification
The virus in nasopharyngeal and oropharyngeal swab samples and 
respiratory tissue, including bronchi and six lobes of the lungs, was 
quantified using reverse transcription quantitative polymerase chain 
reaction (RT-qPCR), and the TCID50 was determined. Briefly, swab 
samples were centrifuged (1600g for 10 min), and the supernatants 
were filtered through 0.2-m syringe filters. Lung and bronchus 
samples were homogenized using a Precellys Homogenizer (Bertin 
Instruments, Montigny-le-Bretonneux, France) in 10-fold (w/v) 
sterile PBS (pH 7.4). After centrifugation, the supernatants were di-
rectly inoculated into Vero cells and incubated for 3 days at 37°C to 
calculate the values of TCID50/ml. Viral RNA was extracted from 
the supernatants of swab and tissue samples using a QIAamp Viral 
RNA Mini Kit (Qiagen, Germantown, MD, USA). RT-qPCR was 
conducted with a primer/probe set to detect the ORF1b gene as de-
scribed previously (24). Viral RNA copy numbers from swab and 
tissue samples were calculated using the SARS-CoV-2 RNA stan-
dard sample, which was run in parallel with the RT-qPCR reaction.
Holotomography
Holotomography was performed to visualize and acquire images 
of protein complexes. A holotomography microscope (HT-2H, 
Tomocube Inc., Daejeon, Republic of Korea), which is a novel optical 
microscope that uses diffraction tomography to generate three- 
dimensional (3D) holographic images of label-free live cells, was used 
for this purpose. Holotomography provides a 3D refractive index 
distribution of the protein through which several 2D holographic 
images can be obtained from different angles to generate a 3D to-
mogram (25). The details of holotomography function and property 
can be found in the literature (26). The acquired data were processed 
and analyzed with Tomostudio software (Tomocube Inc., Daejeon, 
Republic of Korea). The protein samples, including RBD-P2, RBD-
P2/N, RBD-P2 + alum (RBD-P2 in complex with alum), and RBD- P2/ 
N + alum, were analyzed in this study (fig. S3). All samples were 
prepared at a final concentration of 30 ng/l. To visualize the sam-
ples, a Tomodish (Tomocube Inc., Daejeon, Republic of Korea) was 
used, and 25 l of the sample was loaded into the 20 mm–by–
20 mm well.
Dynamic light scattering measurements
RBD-P2 + alum complex, RBD-P2/N + alum complex, and alum 
alone were prepared at a concentration of 0.1 mg/ml in 0.05 mM 
phosphate buffer [including 300 mM NaCl (pH 7.0)]. Dynamic 
light scattering (DLS) was measured on a ZetaSizer Nano ZS90 
(Malvern Instrument, Worcs, UK) equipped with a 4-mW He-Ne 
laser. All the DLS measurements were performed at 4.0° ± 0.1°C and 
at a scattering angle of 90°. The apparent z-average hydrodynamic 
diameter (Dh) and polydispersity index (PDI; <2/2) were calculat-
ed using the Dispersion Technology Software provided by Malvern.
Histological analysis
Sectioned lung tissue from experimental animals (mG1 to mG3) 
was submerged in 10% (v/v) neutral-buffered formalin, dehydrated, 
paraffin-embedded, and sectioned at a 5-m thickness for histological 
examination. The histopathologists were blinded to group distribu-
tion when this analysis was conducted, and representative histo-
pathological images were obtained and evaluated using Aperio 
ImageScope version 12.3 (Leica Biosystems Pathology Imaging, Buffalo 
Grove, IL, USA). The severity of histopathological changes was de-
termined using a five-point scoring system as follows: 0 = no 
abnormality detected, 1 = minimal, 2 = mild, 3 = moderate, 
4 = moderately severe, and 5 = severe. Distribution was recorded as 
focal, multifocal, and diffused. Recruitment of inflammatory cells 
into the lungs (bronchi or blood vessels) and morphological alter-
ations of the tissue were assessed after hematoxylin and eosin stain-
ing under light microscopy.
Statistical analysis
Data are expressed as medians ± 95% confidence interval. Statistical 
analysis was performed using GraphPad Prism. Analysis was performed 
using a one-way analysis of variance (ANOVA) with Dunnett’s post 
hoc for multiple group comparisons and unpaired t test to compare 
between two groups. The type of analysis and statistical interpreta-
tion of the results are indicated in the figure legends. Differences 
were considered statistically significant when P < 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/22/eabg7156/DC1
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